St. Jude Evening of Hope event in Charlotte raised more than $644,000 this year, bringing the total amount raised to over $2.2 million in the last four years.
Inhibiting the Ezh2 enzyme may be counterproductive for treatment of certain cancers, including the aggressive brain tumor Group 3 medulloblastoma
Pioneering physician sets first cure rate for children with acute lymphoblastic leukemia (ALL)
The TomorrowNite Gala in Boston continues to support
St. Jude, raising over $11 million over the last 26 years.
Guests of the 18th
St. Jude Gourmet Gala enjoyed samplings from the D.C. area's top restaurants and chefs while raising almost $1.2 million for
St. Jude recognized for having exceptional workplace culture based upon employee surveys and an in-depth questionnaire.
The new grant supports the opening of the
St. Jude gene therapy protocol for X-linked SCID at the University of California, San Francisco (UCSF) Benioff Children's Hospital San Francisco.
In his new position, Gottschalk will be responsible for management of the department’s clinical, research and educational activities.
Three genetic changes can help identify children with the high-risk leukemia AMKL likely to benefit from allogeneic stem cell transplants.
St. Jude will be the star of the 74th Annual Golden Globe® Awards on January 8 at galas in The Woodlands, Texas, as well as Chicago, Miami and Minneapolis.
Prolonged infection in infant with leukemia led to discovery of a mutation in the stringent response pathway that helps bacteria tolerate antibiotics.
Esteemed hematologist will lead clinical efforts and related expansions to patient care programs
Mystery sensor protein NLRC3 revealed as a central player in preventing colon cells from becoming cancerous
Research reveals principal tumor suppressor function of ARID1A and suggests that loss of the protein contributes to colon cancer
St. Jude scientists and clinicians present research and thought leadership at the annual meeting of the American Society of Hematology in San Diego.
This year the Wall Street Taste of New York event raised $1.2 million for
St. Jude, bringing the total amount raised over the last 27 years to $42 million.
Researchers identify a microRNA that may be key to restoring normal functioning of a brain circuit and quieting the “voices” of schizophrenia
Ph-like ALL accounts for significant percentage of acute lymphoblastic leukemia in adults, underscoring need for clinical trials of targeted
Celebrity partners join Marlo Thomas in promoting the 13th Annual
Thanks and Giving® campaign.
St. Jude Detroit Gala raised $349,000 this year, bringing the total amount raised for
St. Jude to $1.3 million since 2012.
St. Jude Evening Under the Stars event reached $1 million raised for
St. Jude for the third year in a row.
The MEF2D-rearranged subtype of acute lymphoblastic leukemia (ALL) is linked to poor outcomes. Now a possible targeted therapy has been identified.
Childhood Cancer Survivor Study reveals patients do not report better health status despite gains in life expectancy due to advances in cancer treatment
This year the
St. Jude Miracles on the Bay Gala raised $300,000, making the total amount raised for
St. Jude $960,000 since its inception.
To improve patient safety, hospital leaders should provide feedback that demonstrates to staff the value of reporting safety events and errors.
Research from the Pediatric Cancer Genome Project identifies genomic landscape that contributes to the diversity of core-binding factor acute myeloid leukemia.
Celebrities, media, retail and corporate partners unite during the
® campaign to ask consumers to support
Thanks and Giving St. Jude.
Research from the Pediatric Cancer Genome Project identifies the mechanism of action for two transcription factors underlying a type of B-precursor acute lymphoblastic leukemia.
Richard Shadyac Jr., President and CEO of ALSAC, the fundraising and awareness organization for
St. Jude Children’s Research Hospital, has received the 2016 Responsible CEO of the Year Award from Corporate Responsibility Magazine.
New findings help increase understanding of molecular mechanisms for common forms of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).